HOME >> MEDICINE >> NEWS
Viagra significantly effective, well-tolerated for men taking multiple blood pressure treatments

NEW YORK, May 15, 2002 -- More than 80 percent of men taking two or more drugs for their high blood pressure reported improvement in their erections and their ability to have sexual intercourse after taking Viagra (sildenafil citrate) for 12 weeks to treat their erectile dysfunction (ED), according to data scheduled to be presented at the American Society of Hypertension 17th Annual Scientific Meeting.

The 12-week, study involved 562 men taking two or more antihypertensives drugs. The first six weeks of double-blind treatment was followed by an additional six weeks of open-label treatment with Viagra. After six weeks, Viagra significantly improved erections for 71 percent of the men versus 18 percent taking placebo. In addition, the Viagra group had significantly more successful intercourse attempts, 62 percent, compared to 26 percent on placebo. During the open label extension, more than 80 percent of men who received Viagra had improved erections and intercourse.

This study showed that Viagra is both well-tolerated and effective when used in conjunction with high blood pressure medications which is good news for men who are often forced to choose between treating their hypertension and staying sexually active, said Dr. Thomas G. Pickering of the Zena and Michael A. Weiner Cardiovascular Institute, Mount Sinai School of Medicine in New York.

Investigators did not observe any serious adverse events related to Viagra treatment. The majority of side effects were mild to moderate and short-lived, with the most common including headache, facial flushing, indigestion, dizziness, nasal congestion and abnormal vision. Less than 2 percent of Viagra- and placebo-treated patients discontinued the study due to side effects.

For many men, ED is often an underlying symptom signaling that there may be another significant health issue such as hypertension, said Dr. Pickering.

On average, the study participants had high blood pres
'"/>

Contact: Geoff Cook
212-733-5244
Porter Novelli
15-May-2002


Page: 1 2 3

Related medicine news :

1. U of M researcher says Viagra may cause permanent vision loss in some men
2. Viagra used in stroke recovery study
3. Younger men lead surge in Viagra use, study reveals
4. Viagra (R) can take effect in as little as 14 minutes in many men, study shows
5. Viagra for alleviation of pulmonary hypertension?
6. Viagra helps men with heart failure
7. First study of Viagra(R) in black men demonstrates treatment as effective, well tolerated
8. Mayo Clinic study shows no adverse heart effect for sildenafil (Viagra)
9. Beyond Viagra: other phosphodiesterase inhibitors are candidates for potential therapies
10. Viagra Prescribing Will Be Based On Financial Rather Than Clinical Reasoning
11. UK Faculty Members Find Way To Speed Response Of Viagra

Post Your Comments:
(Date:10/31/2014)... Monica Williams-Murphy MD , advanced care ... the chaos that can occur for people who have ... of Americans who come into the emergency department facing ... for the moment and so are their families." She ... a catalyst for a family to get the critical ...
(Date:10/31/2014)... With all the preparations families carry ... they may overlook one critical area – the potential ... school performance and even behavior. Typical children’s vision screenings ... progressive vision problems, and to address this challenge, Dr. ... initiative: The Awesome Eyes Student Vision Program. , ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Surgery for low back pain ... the United States you live, a new report says. ... back pain at some point in their lives, and ... care for a spine problem," co-author Brook Martin, of ... said in a college news release. In spinal ...
(Date:10/31/2014)... In terms of duration of treatment and cost, ... from accelerated partial breast irradiation (APBI) with proton ... new research from The University of Texas MD ... a cost analysis study based on typical patient ... allowable charges for eight different types of partial ...
(Date:10/31/2014)... lab device to give cancer researchers an unprecedented microscopic ... spread through the body, causing more than 90 percent ... tumor cells travel, the device could uncover new ways ... the university,s Whiting School of Engineering and its Institute ... new system recently in the journal Cancer Research ...
Breaking Medicine News(10 mins):Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 3Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3
(Date:10/31/2014)... Investor-Edge has initiated coverage on the ... Laboratories (NYSE: ABT ), Hologic Inc. (NASDAQ: ... and Covidien PLC (NYSE: COV). Free research on these five ... The US markets on Thursday, October 30, 2014, ended on ... at 17,195.42, up 1.30% and the NASDAQ Composite closed at ...
(Date:10/31/2014)...  Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is ... in combination with gemcitabine, will be reimbursed via the ... cancer from 1 November. In ... th most common cause of cancer mortality. Pancreatic ... the lowest 5-year survival of all common cancers at ...
(Date:10/31/2014)... 31, 2014 Today, Analysts Review ... CELG ), Bristol-Myers Squibb Co. (NYSE: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,Celgene Corporation Research Reports ,On October 23, 2014, Celgene ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
Cached News: